Clinical trial · Interventional
Anti-cancer Potentiality of Saffron Against Hepatocellular Carcinoma
Anti Cancer Potential of Saffron in Hepatocellular Carcinoma
NCT06464380CI-TRIAL-00080941not yet recruitingPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Saffron has recently gained considerable interest for its capacity to interfere with cancer at initiation and promotion stages as well as for cancer treatment. Although saffron and its constituents have been shown to have antitumorigenic and proapoptotic activities in different cancer cell lines. The aim of the current investigation is to identify the anti-cancer potentiality of saffron on hepatocellular carcinoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo | Dietary Supplement | — | UNRESOLVED |
| Saffranal | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- safranal Group
- description
- include 20 HCC patients will receive 50 mg safranal regimen in dose of once per day for six months.
- interventionNames
- Dietary Supplement: Saffranal
- type
- PLACEBO_COMPARATOR
- label
- Control Group
- description
- include 20 HCC patients will receive placebo in the form of once per day for six months.
- interventionNames
- Dietary Supplement: Placebo
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- three months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult male and female patients above 18 years * Patients with end-stage HCC not candidate for curative, loco regional treatment and /or systemic chemotherapy * Patients with available baseline laboratory parameters and contrast- enhancing images after given written consent for research participation. Exclusion Criteria: * Patients who are candidate for curative and/or loco-regional or combination treatment for HCC * Patients with concomitant malignancies other than HCC
References
Publications (4)
- BACKGROUNDAbdullaev FI, Espinosa-Aguirre JJ. Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials. Cancer Detect Prev. 2004;28(6):426-32. doi: 10.1016/j.cdp.2004.09.002. PMID 15582266
- BACKGROUNDAbdullaev FI. Cancer chemopreventive and tumoricidal properties of saffron (Crocus sativus L.). Exp Biol Med (Maywood). 2002 Jan;227(1):20-5. doi: 10.1177/153537020222700104. PMID 11788779
- BACKGROUNDBhandari PR. Crocus sativus L. (saffron) for cancer chemoprevention: A mini review. J Tradit Complement Med. 2015 Jan 28;5(2):81-7. doi: 10.1016/j.jtcme.2014.10.009. eCollection 2015 Apr. PMID 26151016
- BACKGROUNDDas I, Das S, Saha T. Saffron suppresses oxidative stress in DMBA-induced skin carcinoma: A histopathological study. Acta Histochem. 2010 Jul;112(4):317-27. doi: 10.1016/j.acthis.2009.02.003. Epub 2009 Mar 27. PMID 19328523